glp-1 receptor antagonist Mechanisms by which agonists may exert beneficial effects on the Structure-Based Discovery of Orthosteric Non-Peptide

doi:10.2147/CPAA.S497904 Nauck MA, Tuttle KR, Tschp MH, Blher M

This rapid breakdown severely limits its therapeutic potential in native form

"STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (STEP 1)"

According to a report by CareEdge Ratings, Indias potential GLP 1 market is set to expand nearly fivefold, from `1,000`1,200 crore in 2025 to approximately `4,5005,000 crore by 2030

In a few specialised situations a diabetes specialist may consider adding them to insulin in carefully selected people, but this is off-label and needs close monitoring

Increased accessibility can improve continuity of care and reduce treatment discontinuation